Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients

Katsuyoshi Matsuoka, Yasushi Iwao, Takeshi Mori, Atsushi Sakuraba, Tomoharu Yajima, Tadakazu Hisamatsu, Susumu Okamoto, Yuichi Morohoshi, Motoko Izumiya, Hitoshi Ichikawa, Toshiro Sato, Nagamu Inoue, Haruhiko Ogata, Toshifumi Hibi

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

OBJECTIVE: The clinical significance of cytomegalovirus (CMV) reactivation complicating ulcerative colitis (UC) patients has been uncertain. It has therefore remained undetermined whether or not CMV reactivation should be treated in UC patients under immunosuppression. The aim of the study was to clarify the natural history of CMV reactivation in UC patients. METHODS: Sixty-nine UC patients with moderate to severe activity were enrolled in the study. All of the patients were treated with prednisolone, and/or immunosuppressants such as cyclosporine A. We sequentially monitored CMV reactivation every 2 wk up until 8 wk using the CMV antigenemia (Ag) assay and plasma quantitative real-time polymerase chain reaction (PCR) assay for CMV. RESULTS: Immunoglobulin (Ig) G for CMV was positive in 48 patients (69.6%) and negative in 21 patients (30.4%). CMV was reactivated in 25 patients out of the 48 seropositive patients (52.1%) during the study period. The CMV Ag and PCR values were low and none of the patients showed any evidence of CMV infection on biopsy specimens by hematoxylin and eosin staining. While gancylovir (GCV) was not used except in two patients, clinical outcomes including rates of remission and colectomy were not significantly different among the CMV reactivation-positive, -negative, and CMV IgG negative groups. Furthermore, CMV disappeared without GCV in most of the CMV reactivation-positive patients. CONCLUSIONS: CMV is frequently reactivated in active UC patients; however, it disappears without antiviral agents. Therefore, antiviral therapies should not be necessary for most UC patients with only CMV reactivation as long as CMV Ag values are low.

Original languageEnglish
Pages (from-to)331-337
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume102
Issue number2
DOIs
Publication statusPublished - 2007 Feb

Fingerprint

Cytomegalovirus
Ulcerative Colitis
Antiviral Agents
Immunoglobulin G
Colectomy
Cytomegalovirus Infections
Hematoxylin
Eosine Yellowish-(YS)
Immunosuppressive Agents
Prednisolone
Natural History
Immunosuppression
Cyclosporine
Real-Time Polymerase Chain Reaction

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. / Matsuoka, Katsuyoshi; Iwao, Yasushi; Mori, Takeshi; Sakuraba, Atsushi; Yajima, Tomoharu; Hisamatsu, Tadakazu; Okamoto, Susumu; Morohoshi, Yuichi; Izumiya, Motoko; Ichikawa, Hitoshi; Sato, Toshiro; Inoue, Nagamu; Ogata, Haruhiko; Hibi, Toshifumi.

In: American Journal of Gastroenterology, Vol. 102, No. 2, 02.2007, p. 331-337.

Research output: Contribution to journalArticle

Matsuoka, K, Iwao, Y, Mori, T, Sakuraba, A, Yajima, T, Hisamatsu, T, Okamoto, S, Morohoshi, Y, Izumiya, M, Ichikawa, H, Sato, T, Inoue, N, Ogata, H & Hibi, T 2007, 'Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients', American Journal of Gastroenterology, vol. 102, no. 2, pp. 331-337. https://doi.org/10.1111/j.1572-0241.2006.00989.x
Matsuoka, Katsuyoshi ; Iwao, Yasushi ; Mori, Takeshi ; Sakuraba, Atsushi ; Yajima, Tomoharu ; Hisamatsu, Tadakazu ; Okamoto, Susumu ; Morohoshi, Yuichi ; Izumiya, Motoko ; Ichikawa, Hitoshi ; Sato, Toshiro ; Inoue, Nagamu ; Ogata, Haruhiko ; Hibi, Toshifumi. / Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. In: American Journal of Gastroenterology. 2007 ; Vol. 102, No. 2. pp. 331-337.
@article{f3a976db5867417db4584aed661d7560,
title = "Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients",
abstract = "OBJECTIVE: The clinical significance of cytomegalovirus (CMV) reactivation complicating ulcerative colitis (UC) patients has been uncertain. It has therefore remained undetermined whether or not CMV reactivation should be treated in UC patients under immunosuppression. The aim of the study was to clarify the natural history of CMV reactivation in UC patients. METHODS: Sixty-nine UC patients with moderate to severe activity were enrolled in the study. All of the patients were treated with prednisolone, and/or immunosuppressants such as cyclosporine A. We sequentially monitored CMV reactivation every 2 wk up until 8 wk using the CMV antigenemia (Ag) assay and plasma quantitative real-time polymerase chain reaction (PCR) assay for CMV. RESULTS: Immunoglobulin (Ig) G for CMV was positive in 48 patients (69.6{\%}) and negative in 21 patients (30.4{\%}). CMV was reactivated in 25 patients out of the 48 seropositive patients (52.1{\%}) during the study period. The CMV Ag and PCR values were low and none of the patients showed any evidence of CMV infection on biopsy specimens by hematoxylin and eosin staining. While gancylovir (GCV) was not used except in two patients, clinical outcomes including rates of remission and colectomy were not significantly different among the CMV reactivation-positive, -negative, and CMV IgG negative groups. Furthermore, CMV disappeared without GCV in most of the CMV reactivation-positive patients. CONCLUSIONS: CMV is frequently reactivated in active UC patients; however, it disappears without antiviral agents. Therefore, antiviral therapies should not be necessary for most UC patients with only CMV reactivation as long as CMV Ag values are low.",
author = "Katsuyoshi Matsuoka and Yasushi Iwao and Takeshi Mori and Atsushi Sakuraba and Tomoharu Yajima and Tadakazu Hisamatsu and Susumu Okamoto and Yuichi Morohoshi and Motoko Izumiya and Hitoshi Ichikawa and Toshiro Sato and Nagamu Inoue and Haruhiko Ogata and Toshifumi Hibi",
year = "2007",
month = "2",
doi = "10.1111/j.1572-0241.2006.00989.x",
language = "English",
volume = "102",
pages = "331--337",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients

AU - Matsuoka, Katsuyoshi

AU - Iwao, Yasushi

AU - Mori, Takeshi

AU - Sakuraba, Atsushi

AU - Yajima, Tomoharu

AU - Hisamatsu, Tadakazu

AU - Okamoto, Susumu

AU - Morohoshi, Yuichi

AU - Izumiya, Motoko

AU - Ichikawa, Hitoshi

AU - Sato, Toshiro

AU - Inoue, Nagamu

AU - Ogata, Haruhiko

AU - Hibi, Toshifumi

PY - 2007/2

Y1 - 2007/2

N2 - OBJECTIVE: The clinical significance of cytomegalovirus (CMV) reactivation complicating ulcerative colitis (UC) patients has been uncertain. It has therefore remained undetermined whether or not CMV reactivation should be treated in UC patients under immunosuppression. The aim of the study was to clarify the natural history of CMV reactivation in UC patients. METHODS: Sixty-nine UC patients with moderate to severe activity were enrolled in the study. All of the patients were treated with prednisolone, and/or immunosuppressants such as cyclosporine A. We sequentially monitored CMV reactivation every 2 wk up until 8 wk using the CMV antigenemia (Ag) assay and plasma quantitative real-time polymerase chain reaction (PCR) assay for CMV. RESULTS: Immunoglobulin (Ig) G for CMV was positive in 48 patients (69.6%) and negative in 21 patients (30.4%). CMV was reactivated in 25 patients out of the 48 seropositive patients (52.1%) during the study period. The CMV Ag and PCR values were low and none of the patients showed any evidence of CMV infection on biopsy specimens by hematoxylin and eosin staining. While gancylovir (GCV) was not used except in two patients, clinical outcomes including rates of remission and colectomy were not significantly different among the CMV reactivation-positive, -negative, and CMV IgG negative groups. Furthermore, CMV disappeared without GCV in most of the CMV reactivation-positive patients. CONCLUSIONS: CMV is frequently reactivated in active UC patients; however, it disappears without antiviral agents. Therefore, antiviral therapies should not be necessary for most UC patients with only CMV reactivation as long as CMV Ag values are low.

AB - OBJECTIVE: The clinical significance of cytomegalovirus (CMV) reactivation complicating ulcerative colitis (UC) patients has been uncertain. It has therefore remained undetermined whether or not CMV reactivation should be treated in UC patients under immunosuppression. The aim of the study was to clarify the natural history of CMV reactivation in UC patients. METHODS: Sixty-nine UC patients with moderate to severe activity were enrolled in the study. All of the patients were treated with prednisolone, and/or immunosuppressants such as cyclosporine A. We sequentially monitored CMV reactivation every 2 wk up until 8 wk using the CMV antigenemia (Ag) assay and plasma quantitative real-time polymerase chain reaction (PCR) assay for CMV. RESULTS: Immunoglobulin (Ig) G for CMV was positive in 48 patients (69.6%) and negative in 21 patients (30.4%). CMV was reactivated in 25 patients out of the 48 seropositive patients (52.1%) during the study period. The CMV Ag and PCR values were low and none of the patients showed any evidence of CMV infection on biopsy specimens by hematoxylin and eosin staining. While gancylovir (GCV) was not used except in two patients, clinical outcomes including rates of remission and colectomy were not significantly different among the CMV reactivation-positive, -negative, and CMV IgG negative groups. Furthermore, CMV disappeared without GCV in most of the CMV reactivation-positive patients. CONCLUSIONS: CMV is frequently reactivated in active UC patients; however, it disappears without antiviral agents. Therefore, antiviral therapies should not be necessary for most UC patients with only CMV reactivation as long as CMV Ag values are low.

UR - http://www.scopus.com/inward/record.url?scp=33846508534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846508534&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.00989.x

DO - 10.1111/j.1572-0241.2006.00989.x

M3 - Article

C2 - 17156136

AN - SCOPUS:33846508534

VL - 102

SP - 331

EP - 337

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -